Adenoid Cystic Carcinoma Of Lung Research Articles

A population study comparing tracheal and lung adenoid cystic carcinoma.

Thoracic adenoid cystic carcinoma (ACC) is rare, and the differences between tracheal and lung lesions have not been fully understood. Patients were identified from a Chinese cancer center (FUSCC) (2005-2022) and the Surveillance, Epidemiology, and End Results (SEER) database (2000-2019). Incidence was calculated and trends were quantified. Clinicopathological features and overall survival (OS) were analyzed. Nomograms predicting OS were constructed. Totally, 55 tracheal adenoid cystic carcinoma (TACC) and 25 lung and bronchus adenoid cystic carcinoma (LACC) were included in a Chinese cohort, 121 TACC and 162 LACC included in the SEER cohort. There were larger tumor sizes, more lymph nodes and distant metastases for LACC than TACC patients. TACC patients are more likely to get local treatments. Patients with LACC had significantly worse median OS than patients with TACC (SEER cohort: 68.0 months vs. 109.0 months, p = 0.001, Chinese cohort: 62.9 months vs. 124.8 months, p = 0.061). Age, lymph node metastasis, distant metastasis and local treatment were identified as independent prognostic factors for OS of TACC. Distant metastasis and local treatment were identified for LACC. Specifically, surgery alone or in combination with radiotherapy is crucial for improving survival in both TACC and LACC. Only TACC benefits from radiotherapy alone, while chemotherapy does not improve survival for either. The nomograms constructed using these factors revealed good prognostic accuracy. LACC is more aggressive and has a worse prognosis than TACC. TACC patients have more opportunities for local treatment, which is important for the prognosis of both TACC and LACC. Nomograms were created for TACC and LACC to aid in personalized survival predictions and clinical decisions.

An Optimized Method to Culture Human Primary Lung Tumor Cell Spheroids

Lung cancer is the leading cause of cancer mortality worldwide, with a median survival rate at 5 years of less than 20%. While molecular mapping aids in selecting appropriate therapies, it cannot predict personalized treatment response and long-term efficacy. For addressing these challenges, there is a great need for functional tests. Within this context, we developed patient-derived spheroids (PDS) from tumor and adjacent normal tissue to biomimic the respective tissue for assessing the personalized drug treatment response in vitro. Surgically resected lung specimens were used to generate spheroids using a two-step culture procedure. Flow cytometry and immune staining enabled the characterization of different cell populations resulting from the lung samples. PDS phenotype, cell proliferation and apoptosis were evaluated. Differential gene expression between tumor and adjacent normal tissue was analyzed via RT-qPCR. PDS drug sensitivity was assessed using a cell metabolic assay in response to two chemotherapeutic drug combinations. Cellular and molecular analysis revealed the proportion of epithelial cells, fibroblasts, and immune cells in the patients’ tissue samples. Subsequently, PDS models from tumor and normal lung were successfully established using the expanded epithelial cells. As a proof of concept, an analysis of the drug treatment using PDS of lung adenoid cystic carcinoma exhibited a dose-dependent effect in response to cisplatin/etoposide and cisplatin/paclitaxel. Our spheroid model of both tumor and non-tumor lung cells holds great promise for enhancing the treatment efficacy in the cancer patients.

A Comparative Population-Based Study of Tracheal and Lung Adenoid Cystic Carcinoma

Thoracic adenoid cystic carcinoma (ACC) is very rare, and its clinicopathological characteristics, treatment and prognosis have not been fully elucidated. Previous studies did not differentiate between tracheal and lung lesions. We identified tracheal ACC (TACC) and lung and bronchus ACC (LACC) patients from our cancer center (from 2005 to 2022) and the Surveillance, Epidemiology, and End Results (SEER) database (from 2000 to 2009). Incidence was calculated and trends were quantified. Significant prognostic factors for overall survival (OS) were reviewed and analyzed by using Cox proportional hazards regression. Then, two nomograms predicting OS of TACC and LACC were constructed based on the SEER database and validated externally by using the separate cohort. There was an upward trend from 2000 to 2019 for LACC while a downward trend from 2000 to 2009 was shown for TACC. Totally, 55 TACC and 25 LACC were included in our cohort, 121 TACC and 162 LACC included in the SEER cohort. There were larger tumor sizes, more lymph nodes and distant metastases for LACC patients than TACC patients. The proportion of patients receiving radiotherapy were higher for TACC than LACC. More patients with TACC received surgery and perioperative radiotherapy than those with LACC. Patients with LACC had significantly worse OS than patients with TACC (SEER cohort: 93.7 mons vs. 127.0 mons, p = 0.001, our cohort: 72.2 months vs. 130.8months, p = 0.061). Age, lymph node metastasis, distant metastasis and radiation and/or surgery were identified as independent prognostic factors for OS of TACC. Laterality, distant metastasis and surgery were identified for LACC. The discrimination of the nomogram revealed good prognostic accuracy and clinical applicability as indicated by C-index values of 0.753 and 0.833 for the training cohort and the external validation cohort for TACC, and 0.739 and 0.786 for LACC. TACC and LACC are different in incidence, clinical features, prognosis. Compared with LACC, radiotherapy combined with surgery is more important for TACC. Two nomograms were established for TACC and LACC respectively to help physicians make more individualized survival predictions and clinical decisions.

A Rare Case of Primary Adenoid Cystic Carcinoma of Lung

A 33-year-old male presented with repeated episodes of blood-streaked sputum for last one-and half-year. Chest radiograph showed consolidation in the right lower zone. Fibreoptic bronchoscopy revealed an endoluminal growth in the right lower lobe bronchus. Histopathological examination of bronchoscopic biopsy specimen confirmed adenoid cystic carcinoma.

Adenoid Cystic Carcinoma Bronchus - A Case Report

Primary adenoid cystic carcinoma of lung is an unusual thoracic neoplasm, which is considered as a slow-growing low-grade malignancy. Usually, it is diagnosed at a higher clinical stage and is difficult to resect due to its central location. A 48-year-old female presented with history of breathlessness. On chest Xray and CT-Thorax showed well defined soft tissue lesion in left main bronchus. She underwent left pneumonectomy and subcarinal node dissection. Histopathological examination was consistent with Adenoid Cystic Carcinoma Bronchus.

Bilateral kidney metastases from adenoid cystic carcinoma of lung: a case report and literature review

Adenoid cystic carcinoma (ACC) is a rare malignant tumor, usually arising from salivary glands and rarely found in other locations. ACC is characterized by asymptomatic course, slow growth pattern, perineural invasion and high incidence of late metastasis. Renal localization of metastasis is rare. Only 12 cases of renal metastasis were published and, to our best knowledge, no case of bilateral metastasis to the kidney has ever been reported. We present a case of a 58years old woman with bilateral renal metastasis from ACC of the right lung after fourteen years from lobectomy and radiotherapy for the primary presentation. The patient underwent bilateral robot-assisted partial nephrectomy in a two-stage approach. Despite its rare incidence and slow growth, ACC metastasis may simulate primary papillary renal carcinoma and occur many years after primary treatment. Therefore, lifelong follow-up, including abdominal imaging, is recommended.

Clinicopathological features of lung salivary gland-type tumors

Objective: To study the clinicopathological characteristics of lung salivary gland-type tumors (SGT), and to compare with the corresponding primary SGT in salivary glands. Methods: Twenty-three cases of lung SGT were retrieved from the files of Peking University First Hospital from January 2004 to September 2018. The morphology, immunophenotype, genotype and outcome of these cases were analyzed. Results: The 23 patients included 13 males and 10 females, with age range of 13-79 years (median 54 years). There were 11 cases of adenoid cystic carcinoma, 10 cases of mucoepidermoid carcinoma (MEC), one case each of clear cell carcinoma and myoepithelioma. The morphology and immunophenotype of lung SGT were very similar to their counterparts in salivary gland. MYB rearrangement was detected in one of 11 adenoid cystic carcinomas. MAML2 rearrangement was detected in all the MECs. EWSR1 rearrangement was detected in the one case of clear cell carcinoma. Of patients with adenoid cystic carcinoma, the survival time was more than 60 months (three cases), 52 months (one case), and 12-36 months (three cases). There was no recurrence and death in seven cases of MEC with follow-up results. One case of clear cell carcinoma recurred after 52 months of follow-up. Conclusions: Although the SGT of lung and their counterparts in salivary gland are very similar in their morphology, immunophenotype, genotype and prognosis, there are also some differences between each other. MYB rearrangement can be detected in most adenoid cystic carcinomas of salivary gland, but rarely in lung adenoid cystic carcinoma. The prognosis of patients with lung MEC is better than that of patients with salivary gland MEC, while the prognosis of patients with lung adenoid cystic carcinoma is worse than that of patients with salivary gland adenoid cystic carcinoma.

A series of patients with unusual lung cancers with unusual presentations

Lung malignancies have become increasingly prevalent. Occasionally, an unusual tumour is diagnosed, or a common tumour type presents unusually. This case report reviews 3 cases of thoracic neoplasm, including two cases of uncommon cancers (primary lung adenoid cystic carcinoma and thoracic desmoplastic small round cell high-grade sarcoma) and an atypical presentation of malignant mesothelioma.

Low recurrence of lung adenoid cystic carcinoma with radiotherapy and resection.

Adenoid cystic carcinoma is a rare cause of thoracic malignancy, and the prognosis may depend on the extent of surgical resection and adjuvant radiotherapy. Complete resection has low rates of local recurrence but is complicated by the involvement of central airways. Adjuvant radiotherapy is frequently recommended but unproven. We describe the technicalities of radical resection and adjuvant radiotherapy using the primary endpoint of local recurrence and secondary endpoints of locoregional (mediastinal) recurrence and distant metastasis. Resections were classed as microscopically and macroscopically clear (R0) or only macroscopically clear (R1). Twelve patients (eight males) diagnosed between 1999 and 2016, with an average age of 44 ± 12 years, were included. Six of these were operable (operative group), and six had non-resectable lesions (radiotherapy group). In the operative group, three had tracheal disease and three had bronchial disease. Tracheal lesions underwent excision with tracheal anastomosis (all R1 resections). Main bronchial lesions underwent complete excision via pneumonectomy (two R0 and one R1 resections). All these patients received 50-60 Gray of adjuvant radiotherapy. At an average follow-up of 6.1 ± 4.3 years, no patient had local recurrence, two had locoregional recurrence and four had distant metastasis. The radiotherapy group received 60-70 Gray as definitive therapy, and at an average follow-up of 5.4 ± 4.2 years, three had locoregional recurrence and four had distant metastasis. Our case series consolidates evidence that early radical resection and radiotherapy is associated with a low risk of local recurrence in patients with thoracic adenoid cystic carcinoma.

The clinicopathological features and curative effect of the bronchoscopic interventional therapy combined with radiotherapy for the treatment of locally recurrent lung adenoid cystic carcinoma

Objective: To explore the clinical value of endoscopic interventional therapy for locally recurrent primary lung adenoid cystic carcinoma (ACC). Methods: The clinical data of 42 patients with locally recurrent ACC were retrospectively analyzed, and the differences of tracheal and bronchial diameter, airway scoring grade and airway obstruction degree before and after treatment were compared among three treatment methods: bronchoscopic interventional therapy + palliative radiotherapy, interventional therapy alone, and non-interventional therapy. Log rank test and Cox proportional risk model multi-factor analysis were used to determine the prognostic factors of ACC patients with local recurrence, and the long-term effect of bronchoscopic interventional therapy on ACC with local recurrence was determined. Results: The median overall survival of 42 patients was 59 months and 5-year survival rate was 54.2%.Univariate analysis showed that vascularized cancer, pleural invasion, pulmonary atelectasis, incisal margin, microscopic classification, tumor diameter, initial TNM stage, ki-67 index, and treatment after local recurrence were associated with long-term survival of ACC patients with local recurrence (all P<0.05). Cox multivariate regression analysis showed that margin status (RR=0.272, P=0.011), tumor diameter (RR=2.586, P=0.005), initial TNM staging (RR=0.369, P=0.035), ki-67 index (RR=3.569, P<0.001), and treatment methods after local recurrence (RR=0.126, P<0.001) were independent factors influencing the prognosis of ACC patients with local recurrence. After three months of treatment, the tracheal bronchus diameters, rating of shortness of breath, and degree of airway obstruction were all improved significantly (all P<0.05), both in the interventional therapy + palliative radiotherapy group [(14.5±2.8 mm, 0.86±0.45, (14.50±10.67)%, respectively], and the interventional therapy alone group [(13.7±2.3) mm, 0.97±0.25, (15.38±12.02)%, respectively]. Meanwhile, the difference before and after non-interventional therapy was not statistically significant (all P>0.05). 5-year overall survival rates were 55.8%, 46.6% and 42.6% for patients undergoing interventional therapy+ palliative radiotherapy, interventional therapy alone, and non-interventional therapy after recurrence, with statistically significant differences (P=0.015). Patients underwent bronchial endoscopic interventional therapy and palliative radiotherapy had the best efficacy of treatment. Conclusion: Endoscopic interventional therapy plus palliative radiotherapy is an effective local palliative treatment for locally recurrent ACC patients, which can rapidly relieve airway stenosis, improve the quality of life of patients and prolong the survival time of patients.

Adenoid cystic carcinoma of lung: An oncologic rarity treated with definitive chemo-radiation

Adenoid Cystic Carcinoma is a rare variant of adenocarcinoma originating mainly from salivary glands of the head and neck region distributed throughout the upper aerodigestive tract with a propensity for perineural invasion. Primary adenoid cystic carcinoma of lungs is exceedingly rare accounting for a mere 0.04 to 0.2 percent of all pulmonary neoplasms. The existing scant case reports about this lung malignancy mostly describe small lung lesions managed with upfront surgery followed by adjuvant radiotherapy. We hereby present this case of primary lung parenchymal pathology where the disease was treated with definitive chemo-radiation and to the best of our knowledge; this case is one of the rarest and earliest reports of upfront chemo-radiation in an inoperable primary lung parenchymal ACC. A 43-year-old woman presented with complaints of cough, severe dyspnea, right sided chest pain associated with occasional hemoptysis. Radiographic imaging of thorax showed a large mass lesion with smooth margins measuring 10.2 × 7.3 × 6.8 cm right lower lobe with invasion of adjacent vital structures. Image guided biopsy and immunohistochemical analysis confirmed the diagnosis. She was eventually treated with definitive radiotherapy with concurrent chemotherapy as she was deemed inoperable. Post therapy evaluation by imaging showed a partial response to chemo-radiation, however there was significant symptomatic relief. In view of CD 117 positivity, she has started on oral imatinib mesylate. Presently she is on follow up with a karnofsky performance status of 90%. A thorough review of literature also reveals that our case may be the largest adenoid cystic primary parenchymal pulmonary pathology ever reported.

Adenoid cystic carcinoma of lung: a very unusual presentation

&lt;p class="abstract"&gt;&lt;span lang="EN-US"&gt;Adenoid Cystic Carcinoma (ACC) is a rare malignancy of the lung arising from the main bronchial division, sub mucosal glands of large airways. Initially it was suspected as a non-resolving pneumonia, which did not respond to empirical antibiotics. Contrast Enhanced Computer Tomography (CECT) of thorax was suggestive of malignancy, bronchoscopic biopsy was suggestive of adenoid cystic carcinoma. The mainstay of treatment is surgical resection (lobectomy, pneumonectomy). As the tumor is radiosensitive, radiotherapy can be used following surgery in the treatment.&lt;/span&gt;&lt;/p&gt;

Primary adenoid cystic carcinoma in the peripheral lung: a cytological, histopathological and immunohistochemical report of two cases

Primary adenoid cystic carcinoma (ACC) of the peripheral lung is a rare entity. Here we report two cases of primary ACC. Case 1 is an 84-year-old male with a past-medical history of cecal cancer presented with a 10 mm left upper lung nodule. Case 2 is a 40-year-old female who presented with 30 mm right upper lobe. Intraoperative (Case 1) and pre-operative (Case 2) histopathologic and cytologic diagnoses were consistent with a primary peripheral lung ACC. An upper lobectomy±mediastinal lymph node dissection was performed and immunohistochemical staining with thyroid transcription factor (TTF)-1, c-KIT and MYB on the excision specimen confirmed our diagnosis.

Clinically Relevant Gene Sequencing in Lung Cancer: Metastatic Non-Small Cell Lung Cancer

Clinically Relevant Gene Sequencing in Lung Cancer: Metastatic Non-Small Cell Lung Cancer

Metachronous adenoid cystic carcinoma in the peripheral lung and at base of the tongue.

Primary lung adenoid cystic carcinoma (ACC) is extremely rare and accounts for approximately 0.1%-0.2% of all lung cancers. ACC of the head and neck has generally been regarded as a slow-growing, low-grade malignancy which has a tendency for local recurrence and frequent distant metastasis. When ACC of the lung is identified, physicians must determine whether it represents distant metastasis or a primary lung cancer. Thyroid transcription factor-1 staining is one of the most useful methods to differentiate primary from metastatic lesions in lung cancer. Herein we report a case of metachronous, not synchronous, ACC at the peripheral lung followed by ACC presentation at the base of the tongue, and review of relevant literatures.

Primary adenoid cystic carcinoma of lung: A case report and review of the literature

Primary adenoid cystic carcinoma of lung is an unusual thoracic neoplasm, which is considered as a slow-growing low-grade malignancy. The primary treatment for this tumor is surgery. The role of radiotherapy, chemotherapy, and targeted agents is less well defined. Here we report a case of inoperable adenoid cystic carcinoma of the lung in a 42-year-old male, presenting with an unusual aggressive behavior. The patient received radiotherapy and oral tyrosine kinase inhibitor imatinib with effective palliation.

Primary lung adenoid cystic carcinoma: a case report and review of the literature

Adenoid cystic carcinoma (ACC) is a rare low-grade malignant epithelial tumor that usually originates in the salivary glands. It shows a slow progression and metastasizes rarely. A 74-year-old male patient was admitted to our clinic due to pulmonary lesions seen on a chest-X ray coincidentally. The patient, 6 years before admission, was operated on for a peptic ulcer perforation and a right hilar mass lesion, and bibasilar pulmonary nodular lesions were also found on his chest radiograph. A bronchoscopic biopsy revealed ACC and surgical treatment was offered to the patient; however, he refused it. The patient, who had a 130-pack-year smoking history, was asymptomatic on admission to our clinic. Since metastatic pulmonary lesions were present, the patient was diagnosed with stage IV lung cancer and given chemotherapy. Thorax computerized tomography, performed after treatment, revealed no change in the size or number of pulmonary lesions, and the patient has been followed since then and is still asymptomatic. This case of metastatic ACC was reported, after a review of the literature, as being a rare case, as the patient revealed no symptoms from the time of diagnosis until the end of treatment.

Carcinoma adenóide quístico recorrente. Revisão a propósito de um caso clínico

The adenoid cystic carcinoma is a malignant epithelial glandular type neoplasia, occurring frequently in the salivary and mammary glands, and rarely in the lung, and is responsible for 0.2% of lung tumours.These tumours present a slow growth and prolonged clinical course, and are characterised by their infiltrative nature and tendency towards late local recurrence.The authors present a case of a woman with adenoid cystic lung carcinoma diagnosed after investigation of a lung nodule, submitted to surgical resection with curative intention, whose follow-up identified late recurrence, 9 years after surgery.The present case emphasises the need for a prolonged surveillance, due to the potential late recurrence of this kind of tumour. The article reviews clinical and pathological features of lung adenoid cystic carcinoma, as well as therapeutic options, namely for prevention of recurrence.Rev Port Pneumol 2009; XV (1): 101-107

Primary adenoid cystic carcinoma of the lung: A clinicopathologic study

Background Primary adenoid cystic carcinoma (ACC) of lung is a rare but distinctive salivary gland-type malignant epithelial neoplasm.

Adenoid Cystic Carcinoma of the Lung

Primary adenoid cystic carcinoma of lung (ACCL) represents one of a group of salivary-type tumors of lung, likely originating from submucosal seromucinous glands in the pulmonary bronchial tree. Although it comprises less than 1% of all primary lung carcinomas, ACCL is considered the second most common primary salivary-type tumor of lung, after mucoepidermoid carcinoma. Typically, patients with ACCL present at a younger age than those with other primary lung carcinomas, although the age range is broad and ranges from the second to eighth decades. ACCL shares histologic and immunophenotypic features with ACC of salivary gland location, and exhibits a similar infiltrative growth pattern with a propensity for perineural invasion. Treatment is primarily surgical, and therefore complete surgical resection, with negative bronchial surgical margins at intraoperative frozen section, is important for the possibility of cure.